GHIT Fund requests Proposals for Drug Development
The Global Health Innovative Technology (GHIT) Fund endeavours to further facilitate collaboration & funding of global health technology R & D, to build momentum, and to demonstrate action and results. GHIT Fund has the Hit-to-Lead Platform (HTLP) which is designed to leverage medicinal chemistry expertise in Japan and facilitate access to Japanese companies or academic organizations’ relevant and diverse compounds for drugs development to address malaria, tuberculosis, Chagas disease, and Visceral leishmaniasis.
GHIT Fund is looking for drug hits (Plasmodium spp. IC50 < 1 µM) derived from Japanese compound libraries to convert them into lead series through a comprehensive assessment of chemical integrity, synthetic accessibility, scalability and novelty, functional behaviour, and structure-activity relationships (SAR), as well as bio-physiochemical and absorption, distribution, metabolism and excretion (ADME) properties.
HTLP projects will be funded for a period of up to two years and GHIT Fund requires each HTLP project to have a collaboration with at list one of the three leading drug development PDPs as a partner:
- Medicine for Malaria Venture (MMV)
- Drugs for Neglected Diseases initiative (DNDi)
- Global Alliance for TB Drug Development (GATB)
Interested applicants must send their proposals by email to HTLPResponse@ghitfund.org no later than 10:00 am Tokyo time on September 2, 2019.
For more information see here.